Results 21 to 30 of about 421,641 (311)

Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone (ACTH)

Frontiers in Neurology, 2013
Relapses in multiple sclerosis (MS) are disruptive and frequently disabling for patients, and their treatment is often a challenge to clinicians. Despite progress in the understanding of the pathophysiology of MS and development of new treatments for ...
Amy ePerrin Ross, Aliza eBen-Zacharia, Colleen J Harris, Jennifer eSmrtka   +3 more
doaj   +1 more source

Correction to: Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)—study protocol for a randomised controlled trial

Trials, 2021
An amendment to this paper has been published and can be accessed via the original article.
Anne Christin Rahn, Lisa Wenzel, Andrea Icks, Alexander Stahmann, Jutta Scheiderbauer, Kristina Grentzenberg, Markus Vomhof, Joseph Montalbo, Tim Friede, Christoph Heesen, Sascha Köpke   +10 more
doaj   +1 more source

Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial

BMJ Open, 2021
Introduction Process evaluations accompanying complex interventions examine the implementation process of the underlying intervention, identify mechanisms of impact and assess contextual factors.
Christoph Heesen, Sascha Köpke, Lisa Wenzel, Jutta Scheiderbauer, Markus van de Loo, Anne Christin Rahn   +5 more
doaj   +1 more source

Radiological Presentation of a Patient With Multiple Sclerosis and Hepatic Disorder

Case Reports in Clinical Practice, 2020
In this case study, we presented the radiological characteristics of a 43-year-old female patient diagnosed with Multiple Sclerosis (MS). Following mitoxantrone administration, she developed liver failure.
Saeideh Salehizadeh, Abdorreza Naser Moghadasi   +1 more
doaj   +1 more source

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting [PDF]

PeerJ, 2016
Background Magnetic resonance imaging (MRI) is the best biomarker of inflammatory disease activity in relapsing remitting Multiple Sclerosis (RRMS) so far but the association with disability is weak.
Johanna von Gumberz, Mina Mahmoudi, Kim Young, Sven Schippling, Roland Martin, Christoph Heesen, Susanne Siemonsen, Jan-Patrick Stellmann   +7 more
doaj   +2 more sources

Autoimmunity to a ribonucleoprotein drives neuron loss in multiple sclerosis models

Neurobiology of Disease, 2022
Neurodegeneration, the progressive loss or damage to neurons and axons, underlies permanent disability in multiple sclerosis (MS); yet its mechanisms are incompletely understood.
Cole D. Libner, Hannah E. Salapa, Catherine Hutchinson, Todd E. Stang, Patricia A. Thibault, S. Austin Hammond, Michael C. Levin   +6 more
doaj   +1 more source

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)

BMC Immunology, 2013
BackgroundMicroRNA are small noncoding RNA molecules that are involved in the control of gene expression. To investigate the role of microRNA in multiple sclerosis (MS), we performed genome-wide expression analyses of mRNA and microRNA in T-cells from MS
M. Jernås, C. Malmeström, M. Axelsson, I. Nookaew, H. Wadenvik, J. Lycke, B. Olsson   +6 more
semanticscholar   +1 more source

Digital Twins for Multiple Sclerosis

Frontiers in Immunology, 2021
An individualized innovative disease management is of great importance for people with multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional disease.
Isabel Voigt, Hernan Inojosa, Anja Dillenseger, Rocco Haase, K. Akgün, T. Ziemssen   +5 more
semanticscholar   +1 more source

Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2020
: The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms of multiple sclerosis (MS).
M. Freedman, V. Devonshire, P. Duquette, P. Giacomini, F. Giuliani, Michael C Levin, X. Montalban, S. Morrow, Jiwon Oh, D. Rotstein, E. Yeh   +10 more
semanticscholar   +1 more source

Two-locus linkage analysis in multiple sclerosis (MS).

Genomics, 1994
One of the major challenges in genetic linkage analyses is the study of complex diseases. We demonstrate here the use of two-locus linkage analysis in multiple sclerosis (MS), a multifactorial disease with a complex mode of inheritance.
P. Tienari, J. Terwilliger, J. Ott, J. Palo, L. Peltonen   +4 more
semanticscholar   +1 more source